Literature DB >> 18318968

Delay between pregnancy confirmation and sickle cell and [corrected] thalassaemia screening: a population-based cohort study.

Elizabeth Dormandy1, Martin C Gulliford, Erin P Reid, Katrina Brown, Theresa M Marteau.   

Abstract

BACKGROUND: Antenatal sickle cell and thalassaemia screening sometimes occurs too late to allow couples a choice regarding termination of affected fetuses. The target gestational age for offering the test in the UK is 10 weeks. AIM: To describe the proportion of women screened before 70 days' (10 weeks') gestation and the delay between pregnancy confirmation in primary care and antenatal sickle cell and thalassaemia screening. DESIGN OF STUDY: Cohort study of reported pregnancies.
SETTING: Twenty-five general practices in two UK inner-city primary care trusts offering universal screening.
METHOD: Anonymised data on all pregnancies reported to participating general practices was collected for a minimum of 6 months.
RESULTS: There were 1441 eligible women intending to proceed with their pregnancies, whose carrier status was not known. The median (interquartile range [IQR]) gestational age at pregnancy confirmation was 7.6 weeks (6.0-10.7 weeks) and 74% presented before 10 weeks. The median gestational age at screening was 15.3 weeks (IQR = 12.6-18.0 weeks), with only 4.4% being screened before 10 weeks. The median delay between pregnancy confirmation and screening was 6.9 weeks (4.7-9.3 weeks) After allowing for practice level variation, there was no association between delay times and maternal age, parity, and ethnic group.
CONCLUSION: About 74% of women consulted for pregnancy before 10 weeks' gestation but fewer than 5% of women were screened before the target time of 10 weeks. Reducing the considerable delay between pregnancy confirmation in primary care and antenatal sickle cell and thalassaemia screening requires methods of organising and delivering antenatal care that facilitate earlier screening to be developed and evaluated.

Entities:  

Mesh:

Year:  2008        PMID: 18318968      PMCID: PMC2249790          DOI: 10.3399/bjgp08X277267

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  9 in total

1.  Outcomes of universal antenatal screening for haemoglobinopathies.

Authors:  P Greengross; M Hickman; M Gill; B Dugan; S C Davies
Journal:  J Med Screen       Date:  1999       Impact factor: 2.136

2.  Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry.

Authors:  B Modell; R Harris; B Lane; M Khan; M Darlison; M Petrou; J Old; M Layton; L Varnavides
Journal:  BMJ       Date:  2000-02-05

3.  A pilot study of 'fast track' antenatal screening for haemoglobinopathies.

Authors:  J Wright; N Rati; A Kennefick; A Cobley; C McKweon; A Wood
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

4.  Geographical and organisational variation in the structure of primary care services: implications for study design.

Authors:  Geoffrey Adams; Martin Gulliford; Obioha Ukoumunne; Susan Chinn; Michael Campbell
Journal:  J Health Serv Res Policy       Date:  2003-04

Review 5.  Social class, ethnicity and attendance for antenatal care in the United Kingdom: a systematic review.

Authors:  Rachel E Rowe; Jo Garcia
Journal:  J Public Health Med       Date:  2003-06

6.  Audit of process of antenatal screening for sickle cell disorders at a north London hospital.

Authors:  H Neuenschwander; B Modell
Journal:  BMJ       Date:  1997-09-27

7.  Antenatal screening for haemoglobinopathies in primary care: a whole system participatory action research project.

Authors:  Paul Thomas; Lola Oni; Mabel Alli; Judith St Hilaire; Alma Smith; Conan Leavey; Ricky Banarsee
Journal:  Br J Gen Pract       Date:  2005-06       Impact factor: 5.386

8.  The National Service Framework for children, young people and maternity services: developing the evidence base.

Authors:  P Sloper; J Statham
Journal:  Child Care Health Dev       Date:  2004-11       Impact factor: 2.508

9.  Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial.

Authors:  E Dormandy; S Bryan; M C Gulliford; T E Roberts; A E Ades; M Calnan; K Atkin; J Karnon; P M Barton; J Logan; F Kavalier; H J Harris; T A Johnston; E N Anionwu; V Davis; K Brown; A Juarez-Garcia; V Tsianakas; T M Marteau
Journal:  Health Technol Assess       Date:  2010-04       Impact factor: 4.014

  9 in total
  8 in total

1.  Commissioning maternity care: little room for manoeuvre?

Authors:  David Jewell
Journal:  Br J Gen Pract       Date:  2011-10       Impact factor: 5.386

2.  Community-based maternity care in 2008.

Authors:  Mary J Renfrew; Jacque Gerrard; Helen Baston
Journal:  Br J Gen Pract       Date:  2008-03       Impact factor: 5.386

3.  Maximising recruitment and retention of general practices in clinical trials: a case study.

Authors:  Elizabeth Dormandy; Fred Kavalier; Jane Logan; Hilary Harris; Nola Ishmael; Theresa M Marteau
Journal:  Br J Gen Pract       Date:  2008-11       Impact factor: 5.386

4.  Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study.

Authors:  Stirling Bryan; Elizabeth Dormandy; Tracy Roberts; Anthony Ades; Pelham Barton; Ariadna Juarez-Garcia; Lazaros Andronis; Jonathan Karnon; Theresa M Marteau
Journal:  Br J Gen Pract       Date:  2011-10       Impact factor: 5.386

5.  Offering antenatal sickle cell and thalassaemia screening to pregnant women in primary care: a qualitative study of GPs' experiences.

Authors:  Vicki Tsianakas; Michael Calnan; Karl Atkin; Elizabeth Dormandy; Theresa M Marteau
Journal:  Br J Gen Pract       Date:  2010-11       Impact factor: 5.386

6.  Antenatal haemoglobinopathy screening - Experiences of a large Australian Centre.

Authors:  Sylvia Ai; Corrina Cliffe; Giselle Kidson-Gerber
Journal:  Obstet Med       Date:  2020-08-19

7.  Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial.

Authors:  Elizabeth Dormandy; Martin Gulliford; Stirling Bryan; Tracy E Roberts; Michael Calnan; Karl Atkin; Jonathan Karnon; Jane Logan; Fred Kavalier; Hilary J Harris; Tracey A Johnston; Elizabeth N Anionwu; Vicki Tsianakas; Patricia Jones; Theresa M Marteau
Journal:  BMJ       Date:  2010-10-05

Review 8.  Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Authors:  Norita Hussein; Stephen F Weng; Joe Kai; Jos Kleijnen; Nadeem Qureshi
Journal:  Cochrane Database Syst Rev       Date:  2018-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.